regentis

Regentis Biomaterials Moves GelrinC Along Parallel U.S. Clinical and European Commercial Tracks

Fri, 14 Aug 2026 20:33:54 GMT

Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027.
FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group.
In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing process that raises yield approximately 400%.

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between clinical validation and market adoption. Regentis Biomaterials (NYSE American: RGNT) is attempting exactly that, advancing its GelrinC(R) cartilage repair platform along a U.S. clinical track and a European commercial track and scaling of manufacturing at the same time.

The U.S. Program Approaches Its Defining Milestone

GelrinC is a cell-free, off-the-shelf hydrogel implant for focal articular cartilage defects in the knee. Rather than harvesting cells from the patient, expanding them in a laboratory and implanting them during a second surgery, GelrinC arrives ready to use and is implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, then erodes on a synchronized schedule as surrounding cells aggregate and form new tissue inward.

The pivotal SAGE study is enrolling 80 patients under an FDA-approved IDE protocol running across the U.S., Europe and Israel. More than half of the targeted 80 patients have been recruited and treated, with the study incorporating 24-month follow-up. The company reports no serious adverse events observed to date. Regentis is targeting completion of recruitment in the third quarter of 2026, with a premarket approval submission expected to begin at the end of 2027.

Completing enrollment would move the program out of patient recruitment and into data generation, the phase that produces the package a PMA filing rests on.

A Protocol Designed to Reduce Trial Risk

The study design merits attention on its own. FDA permitted a single-arm protocol using a historical microfracture control data package owned by Regentis and drawn from the TiGenix NV1 program, rather than requiring a concurrent randomized control arm. That design reduces the cost and variability associated with recruiting and managing a concurrent control cohort.

It also provides an early read on comparability. According to the company, the first 40 patients closely match the historical control group in baseline characteristics, an important consideration validating the comparability of the two populations.

The clinical foundation beneath that design came from a 56-patient Phase II study followed for up to five years in Northern Europe and Israel. Primary endpoints were met at 24 months, with approximately 100% greater KOOS pain and function improvement compared to microfracture and a mean MOCART imaging score of 88.8 out of 100, providing additional objective and quantitative evidence of quantity and quality of cartilage repair.

Europe Shifts from Approval to Adoption

Europe sits further along because GelrinC has already secured CE Mark approval. The focus there can therefore shift from obtaining initial authorization toward commercialization, surgeon adoption and distribution.

Hands-on surgeon training begins in the third quarter of 2026 at Humanitas Research Hospital in Milan, with additional sessions planned for other major European markets. Those sessions anchor a growing network of European Centers of Excellence intended to function as clinical hubs were experienced orthopedic surgeons train and support other physicians. The clinical site network behind that effort has expanded beyond Northern and Central Europe into Italy and Eastern Europe, adding sites in Pavia, Hamburg, Ljubljana, Timisoara and Belgrade.

On the commercial side, Regentis has been exploring regional distributors to map country priorities and working with European toll manufacturers on commercial sourcing.

Supply Built Ahead of Demand

Manufacturing is the piece that can stall a launch. In July, the European Notified Body approved the company’s next-generation solvent-free process for GelrinC, which Regentis says increases production yield by approximately 400%, or roughly fivefold, from the same manufacturing volume while lowering cost and improving occupational and environmental safety.

The timing may be as important as the magnitude of the improvement. Regentis can enter European commercialization using the higher-yield process.

Two Timelines, One Objective

The significance of the company’s current position lies in convergence rather than in any single announcement. In the United States, Regentis is progressing towards the enrollment milestone that opens the path toward a PMA filing. In Europe, approval is behind it and the remaining work is training, connecting with distributors and supply. Both tracks point at the same outcome: turning years of clinical development into a cartilage repair product that can be manufactured, sold and used on a scale.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

Regentis Biomaterials Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Thu, 13 Aug 2026 20:44:12 GMT

A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company's intellectual property footprint into one of the world's largest cartilage-repair markets.
The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale.
The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial.

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field's largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual property becomes just as important as clinical performance.

Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel for knee cartilage repair delivered in a single procedure of about 10 minutes, with no cell harvesting or laboratory processing. On July 20, the company strengthened its position in one of the world's largest cartilage-repair markets.

Japan: A Substantial and Growing Market for Cartilage Repair

Aging is expanding the patient pool for the cartilage-repair opportunity across every developed market, and Asia is growing fastest. Japan is a marquee example. Published research estimates roughly 25 million people over the age of 40 in Japan have radiographic knee osteoarthritis, including about 8 million with symptomatic disease, while independent market research projects the country's cartilage-repair market will approach $289 million by 2030. Demand is not the question. The competitive question is who can serve the market on a scale. For regenerative medicine companies, geographic expansion requires manufacturing systems capable of supporting broad adoption.

For an Off-the-Shelf Product, the Process Is the Moat

That question turns on manufacturing. Many current cartilage repair approaches rely on cell-based procedures, but their multi-step model, with tissue harvested from the patient, expanded in a laboratory over weeks, then reimplanted, is expensive and difficult to scale, which can involve significant cost and operational complexity. GelrinC is designed around the opposite model: a ready-to-use liquid formulation produced without organic solvents and intended to deliver a simpler, lower-cost alternative to cell-based procedures.

The differentiator is the manufacturing platform behind that formulation. Regentis has developed a solvent-free manufacturing method that raises yield 5-fold, simplifies production, and is built to scale for commercial supply. In a category where an off-the-shelf product only succeeds if it can be manufactured consistently and economically at volume, production capability is a critical commercial differentiator.

IP Protecting a Manufacturing Advantage in a Major Market

The July 20 announcement reinforces that strategy. The Japan Patent Office issued a Notice of Allowance for Regentis's application covering the solvent-free protein-polymer conjugate compositions and manufacturing methods behind GelrinC's ready-to-use formulation. Securing patent protection for that process in Japan helps protect the manufacturing approach that supports GelrinC's scalability and commercial objectives.

"Our proprietary manufacturing technology is a key competitive advantage for GelrinC," said Ehud Geller, CEO and Executive Chairman of Regentis. The allowance further expands a worldwide portfolio of nearly 30 granted patents spanning product composition, surgical technique, and manufacturing methods, with additional applications pending.

From Approval Toward Commercialization

Regentis is moving from clinical proof toward commercial reality. GelrinC holds CE Mark approval in the European Union, where commercialization efforts are beginning in 2026, and its pivotal U.S. trial has passed 50% enrollment, with a premarket approval preparation targeted for the end of 2027. Beyond knee cartilage repair, the Gelrin platform is also being evaluated for additional applications, including smaller joints and earlier-stage osteoarthritis indications.

The clinical case for GelrinC has been building for years through published imaging and outcome data. The Japanese patent allowance highlights that transforming clinical progress into a global commercial product depends not only on therapeutic performance, but also on manufacturing capability and intellectual property protection. While regulatory approval and clinical outcomes remain the ultimate determinants of success, Regentis is building the operational foundation needed to compete in the expanding cartilage-repair market.

NOTE TO INVESTORS : The latest news and updates relating to RGNT are available in the Company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT : IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Wed, 05 Aug 2026 20:19:02 GMT

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production yield by 400%.
The company is advancing commercialization through scalable manufacturing, surgeon training programs, and continued U.S. Phase III clinical progress.
These developments reinforce Regentis' strategy of bringing innovative cartilage repair technology from clinical validation to commercial scale, with unit economics that improve as production volumes build.

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC, its innovative cell-free hydrogel implant for focal knee cartilage repair, with a value proposition that extends across the entire healthcare ecosystem. Designed to simplify treatment while improving clinical outcomes, GelrinC offers meaningful benefits for surgeons, patients, and healthcare payers alike. Recent European regulatory approval for a next-generation solvent-free manufacturing process, which boosts production yield by approximately 400%, strengthens the company’s ability to deliver a practical, scalable solution that addresses longstanding limitations in cartilage repair at a much lower production cost.

Unlike complex cell-based therapies or temporary treatment approaches such as microfracture, GelrinC is designed as an off-the-shelf solution. The ready-to-use hydrogel is delivered during a single procedure lasting roughly 10 minutes, cures in situ, and gradually resorbs as the patient's own cells regenerate durable, hyaline-like cartilage. This combination of procedural simplicity, clinical performance, and favorable economics creates a compelling value proposition for surgeons, patients, and healthcare payers.

The Surgeon Win: Seamless Integration and Procedural Simplicity

Orthopedic surgeons face constant pressure to deliver better outcomes within tight operating room schedules and existing workflows. GelrinC is designed to integrate easily into these orthopedic processes The minimally invasive, single-step procedure takes roughly 10 minutes and requires no cell harvesting, laboratory processing, or staged surgeries.

This streamlined approach fits naturally into the standard surgeon workflows, helping reduce operative complexity compared with many current treatment approaches. With faster ~2-week recovery times (versus 6 weeks or more for some treatments), surgeons can offer patients a more efficient path back to function. Regentis is further supporting adoption through surgeon training programs and European Centers of Excellence, including collaborations with leading institutions such as Humanitas Research Hospital in Milan, Italy.

The Patient Win: Better Outcomes and Faster Return to Life

For patients with focal knee cartilage injuries, durable repair is often more valuable than temporary symptom relief. Clinical data from GelrinC studies show approximately 100% greater improvement in pain and function scores versus microfracture at two years, with MRI evidence of near-native cartilage regeneration and sustained benefits over multiple years.

The shorter recovery period and potential for durable repair translate into quicker returns to work, sports, and daily activities, addressing one of the most frustrating aspects of traditional cartilage treatments.

The Payer Win: Cost-Effectiveness and Value-Based Care

As healthcare systems continue shifting toward value-based care, payers are placing greater emphasis on treatments that improve outcomes while lowering total costs of care. GelrinC aligns well with this shift. As an off-the-shelf product, it avoids the high expenses associated with personalized cell therapies and is expected to the current estimated at $40,000+ cost of cell-based products to one-fourth--~$10,000, while maintaining very strong gross margins. Its shorter 10-minute procedure time, faster patient recovery, and potential to reduce repeat interventions have the potential to improve the overall economic value of treatment for insurers and healthcare systems.

These advantages are especially timely as the U.S. cartilage repair market, estimated at ~$3 billion and encompassing roughly 470,000 annual procedures , continues to grow amid aging populations and rising sports injuries.

Building Commercial Momentum

Regentis is executing on multiple fronts to turn clinical promise into commercial reality. The newly approved solvent-free process lifts production yield by roughly 400% while improving manufacturing efficiency and lowering production costs—important milestones as the company prepares for broader European commercialization.

In the United States, the company continues to advance its pivotal Phase III SAGE trial, which is already over 50% enrolled, under an FDA-approved protocol, and expect to complete enrollment in 2026, while preparing for Premarket Approval (PMA) submission. With CE Mark approval already in hand for Europe, these developments position Regentis to potentially establish GelrinC as the first true off-the-shelf regenerative solution in a market that has long lacked practical, durable options.

Why GelrinC Could Become the Standard of Care

By addressing practical challenges related to surgical workflow, clinical durability, and healthcare economics, GelrinC represents more than an incremental advance in cartilage repair. For investors, the case rests on the same economics: off-the-shelf scalability and a lower production cost base, applied to a U.S. cartilage repair market of roughly 470,000 annual procedures and an estimated $3 billion. The company's continued progress in manufacturing, physician education, and late-stage clinical development demonstrates a deliberate strategy focused on commercial execution as well as clinical innovation.

As current clinical and commercialization milestones continue to build, GelrinC has the potential to reshape the treatment landscape for focal knee cartilage injuries by offering a solution that better aligns the interests of physicians, patients, healthcare systems, and the investors backing them.

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Fri, 24 Jul 2026 20:30:16 GMT

Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions.
Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair.
These developments underscore the company’s broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies.

Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs.

GelrinC’s commercial potential is rooted in the combination of clinical differentiation and practical adoption. The product is designed to deliver advanced cartilage repair through a practical, approximately 10-minute, single-step procedure, without cell harvesting, laboratory expansion, patient-specific manufacturing, or a second surgery. At the same time, clinical data generated to date have shown meaningful and durable improvements in pain and function, together with evidence of high-quality cartilage repair tissue. The result is a rare value proposition in orthopedics: a regenerative treatment designed to be clinically differentiated, economically practical, scalable across surgical centers, and capable of supporting faster return to daily activity and work.

Industry Validation Supports the Regenerative Medicine Thesis

The regenerative medicine sector continues to gain regulatory validation. Recent FDA De Novo authorization of TISSIUM’s suture-less tissue repair platform highlights growing acceptance of advanced biomaterials designed to improve healing and simplify procedures. While addressing a different clinical indication, the milestone reflects broader momentum supporting biomaterial-based regenerative technologies such as Regentis’ GelrinC.

GelrinC Targets a Major Unmet Need

Regentis is pursuing this opportunity through GelrinC, its proprietary hydrogel-based implant designed to support the regeneration of damaged knee cartilage through a simple, single-step procedure. Unlike many existing treatment options that require cell harvesting, laboratory processing, and extended recovery periods, GelrinC is designed as an off-the-shelf solution that can be integrated into standard surgical workflows.

The company’s approach seeks to reduce procedural complexity while promoting durable cartilage regeneration and improved patient outcomes.

A Differentiated Biomaterials Platform

Regentis sits at the convergence of biomaterials engineering, regenerative medicine, and orthopedic innovation. Its proprietary hydrogel implant technology is engineered to support the body’s natural regenerative processes, gradually degrading as hyaline-like cartilage tissue forms.

Clinical data have demonstrated approximately 100% greater pain improvement than microfracture procedures while also showing durable cartilage repair, reinforcing GelrinC’s potential differentiation from both conventional treatments and more complex cell-based therapies.

Significant Commercial Potential

The company’s commercial opportunity is further strengthened by its focus on knee cartilage repair , which represents the largest segment of the cartilage repair market, accounting for approximately 46% of industry revenue. Management estimates the U.S. market opportunity alone exceeds $3 billion annually, providing substantial room for expansion upon regulatory approval and commercial adoption in the United States.

Following CE Mark approval in Europe, Regentis is advancing commercialization through surgeon training, market education, and Centers of Excellence engagement while continuing its Phase III U.S. clinical program.

Multiple Catalysts Underway

With CE Mark approval already secured in Europe and a pivotal Phase III clinical trial underway in the United States, Regentis continues advancing toward a PMA submission with the FDA, providing investors with multiple potential value-driving milestones over the coming years.

Positioned at the Intersection of Innovation and Growth

As regenerative medicine gains broader clinical and regulatory acceptance, Regentis is positioned at the intersection of biomaterials innovation and orthopedic care. With encouraging clinical data, a differentiated platform, and exposure to a multibillion-dollar market opportunity, the company is advancing toward several meaningful commercial and regulatory milestones.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT : IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

Tue, 07 Jul 2026 14:29:41 GMT

Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration.
Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows.
With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions.

What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis ("OA").

Historically, healthcare providers have had limited options for addressing cartilage damage before it progresses to more severe joint deterioration. Conventional microfracture procedures are relatively simple and cost-effective but often produce fibrocartilage with limited long-term durability. Meanwhile, cell-based regenerative therapies can involve multiple surgeries, extensive laboratory processing and substantial treatment costs, creating major barriers to widespread adoption.

Today, advances in regenerative medicine are creating new opportunities to address cartilage damage more effectively and efficiently. Among them is Regentis Biomaterials Ltd. (NYSE American: RGNT) Gelrin C, a cell-free, 10-minute procedure of an off-the-shelf hydrogel designed to support cartilage regeneration while avoiding many of the logistical and economic challenges associated with complex multi-stage procedures.

The commercial thesis behind GelrinC is that cartilage repair does not only need better biology. It needs a product architecture that can be adopted. Hospitals need procedures that fit existing operating room workflows. Surgeons need techniques that are practical to learn and repeat. Payers need solutions that do not carry the logistical and financial burden of individualized cell therapy. GelrinC’s off-the-shelf, cell-free, single-stage design directly addresses those adoption barriers.

The Economic Drain of "Wait and See"

When a cartilage defect is ignored or poorly treated, the financial toll quickly multiplies:

The economic consequences of untreated cartilage damage extend far beyond the initial injury. As cartilage defects progress toward osteoarthritis ("OA"), healthcare costs can rise dramatically through ongoing physician visits, imaging, injections, rehabilitation programs and, in many cases, eventual joint replacement procedures. Studies suggest that the lifetime cost of managing a patient who develops knee OA can exceed $140,000, while a large U.S. claims-based analysis estimated that newly diagnosed knee OA patients incur healthcare costs nearly double those of matched controls. Based on prevalence and treatment utilization data , researchers estimated the annual economic burden of knee OA in the United States at approximately $5.7 billion to $15 billion in financial strain. Beyond direct medical expenses, cartilage injuries often affect younger, active individuals, creating additional costs through reduced productivity, workplace absenteeism and disability.

Disrupted Dynamics: How Gelrin C Rewrites the Financial Math

The challenge for healthcare systems has historically been the lack of an ideal middle ground between relatively inexpensive procedures and more complex regenerative approaches. Conventional microfracture techniques are widely used but often ineffective as they result in fibrocartilage that lacks the durability and biomechanical properties of native cartilage. Meanwhile, cell-based therapies can involve multiple surgical procedures, specialized laboratory processing and significantly higher upfront costs, creating barriers for providers, payers and patients alike.

Regentis Biomaterials believes Gelrin C may offer a different approach. The company's cell-free, off-the-shelf hydrogel is administered in a 10 minute procedure which minimizes trauma while avoiding the logistical complexities associated with harvesting, expanding and reimplanting a patient's cells. Because the treatment is delivered in a single surgical setting, it has the potential to simplify care pathways while reducing many of the costs traditionally associated with advanced cartilage repair.

The Macroeconomic Reality of a 10-minute Procedure

The economic rationale is supported by the product's underlying design. Gelrin C consists of a hydrogel matrix combining polyethylene glycol (PEG) and denatured fibrinogen. The material is applied directly to the cartilage defect and cured with ultraviolet light in approximately 90 seconds, forming a solid matrix that conforms to the defect site. Over time, the implant gradually erodes and resorbs as new tissue develops. According to Regentis, clinical studies have demonstrated the formation of hyaline-like cartilage and sustantial improvements in pain and function, outcomes that could prove increasingly important as healthcare systems seek solutions capable of addressing cartilage damage before it progresses to more costly degenerative joint disease.

From a health economics standpoint, this changes everything. With an estimated 470,000 annual knee cartilage repair cases in the U.S. representing a $3 billion market , insurers have long resisted covering expensive cell-based treatments. Gelrin C eliminates this friction by offering an economic sweet spot: it scales down the cost of advanced regenerative medicine to a level that is easily absorbed by hospital budgets and insurance frameworks, fundamentally preventing the downstream progression to expensive osteoarthritis.

From a health economics perspective, the appeal of Gelrin C lies in its ability to address a significant unmet need without introducing the complexity typically associated with advanced regenerative therapies. With an estimated 470,000 cartilage repair procedures performed annually in the United States, representing a market opportunity of approximately $3 billion, healthcare providers and payers continue to seek solutions that balance clinical outcomes with economic practicality. By utilizing a cell-free, off-the-shelf approach that integrates into existing surgical workflows, Gelrin C is designed to reduce many of the logistical and cost-related challenges that have historically limited broader adoption of regenerative cartilage repair technologies.

As Regentis Biomaterials advances its commercialization efforts, the company is positioning itself within a large and underserved segment of orthopedic medicine. Gelrin C's single-step treatment approach, proprietary hydrogel technology and growing body of clinical data differentiate it from both conventional microfracture procedures and more complex cell-based alternatives. Equally important, the technology has been designed to fit within existing healthcare infrastructure, potentially lowering barriers to physician adoption and reimbursement. If Gelrin C continues to demonstrate its ability to support durable cartilage regeneration while maintaining a practical economic profile, Regentis could be well positioned to participate in the growing demand for regenerative solutions aimed at preserving joint health and delaying the progression of osteoarthritis.

For more information, visit the company’s website at www.regentis.co.il .

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the Company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Regentis Biomaterials (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Thu, 04 Jun 2026 19:35:22 GMT

Humanitas collaboration supports Regentis' physician adoption strategy and broader commercial infrastructure across the European market.
GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution.
Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones.

Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials Ltd. (NYSE American: RGNT) is approaching that transition with GelrinC(R) , its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The opportunity is significant. Approximately 470,000 cases of focal knee cartilage damage are treated annually in the United States, yet physicians still lack a broadly available FDA-approved off-the-shelf regenerative cartilage repair solution. For investors, the central question may be straightforward: what happens if a company successfully introduces a simple regenerative solution into a market where no directly comparable option currently exists?

Beyond the clinical need, GelrinC's simplicity may prove important from a commercialization standpoint. Unlike more complex cell-based therapies that require tissue harvesting, laboratory processing and multiple procedures, GelrinC is designed for straightforward integration into existing surgical workflows. For investors, that combination of procedural simplicity and regenerative potential could support future physician adoption if clinical and regulatory milestones continue to be achieved structural tissue restoration GelrinC has already received CE Mark approval in Europe and is currently being evaluated in a pivotal FDA study that has surpassed 50% enrollment.

Clinical results published to date have demonstrated sustained pain relief and functional improvement for more than five years, while imaging assessments suggesting near-complete structural cartilage repair. For investors, these findings are important because they indicate both improved patient outcomes and structural tissue restoration GelrinC has already received CE Mark approval in Europe and is currently being evaluated in a pivotal FDA study that has surpassed 50% enrollment.

Regentis is also taking visible steps toward commercialization. In April 2026, the company announced a collaboration with Humanitas Research Hospital in Milan and cartilage regeneration expert Prof. Elizaveta Kon to support its European Centers of Excellence strategy. Beyond scientific collaboration, these initiatives may help build physician familiarity, surgeon engagement and future adoption pathways ahead of broader commercialization efforts. Operational preparation is advancing as well. Earlier this year, Regentis announced a solvent-free manufacturing process that more than quadrupled GelrinC production yield per batch while improving efficiency and scalability. Although manufacturing developments often receive less attention than clinical milestones, experienced healthcare investors frequently view manufacturing readiness as an important indicator of commercial preparedness Looking ahead, investors may be focused on several potential value inflection events, including completion of pivotal study enrollment, additional clinical follow-up data, regulatory progress, potential PMA submission and continued commercialization initiatives in Europe. Each milestone has the potential to reduce uncertainty and increase investor attention as the company advances toward possible commercialization. Beyond GelrinC itself, the company's proprietary Gelrin hydrogel platform may also provide future opportunities through additional indications, partnerships or licensing activities.

With regulatory progress, manufacturing scale-up and physician engagement initiatives advancing simultaneously, Regentis appears to be entering a period where execution may become increasingly important to the investment story. As the company moves closer to potential commercialization, investor attention may increasingly focus not simply on whether cartilage regeneration is possible but whether Regentis can successfully convert its clinical foundation into physician adoption, commercial traction and long-term value creation.

For more information, visit the company’s website at www.regentis.co.il .

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the Company’s newsroom at ibn.fm/RGNT .

Regentis Biomaterials and the Off-the-Shelf Opportunity in Knee Cartilage Repair

Fri, 22 May 2026 18:33:44 GMT

Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market
Regentis' GelrinC® is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled
A newly patented solvent-free manufacturing process that increases GelrinC® production yield by 400% signals Regentis' preparation for commercial scale-up as clinical and regulatory milestones approach

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.

Regentis Biomaterials Ltd. (NYSE American: RGNT) is targeting that gap with GelrinC®, its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional treatment pathways.

The Limitations of Today's Standard

For active patients with focal cartilage damage, current treatment options often involve trade-offs.

Microfracture remains widely used because it is relatively straightforward and familiar to orthopedic surgeons, but the tissue it produces is fibrocartilage rather than true hyaline cartilage, making durability a persistent concern. Cell-based procedures offer a more biologically sophisticated approach, but typically require an initial biopsy, weeks of laboratory cell expansion, and a second surgical procedure for implantation. Costs for those approaches can range from approximately $38,000 to $45,000 per case.

Other repair methods may involve harvesting plugs from healthy bone and cartilage and requiring two surgeries, introducing additional trauma through surgical complexity and donor-site concerns. No currently available cartilage repair solution combines off-the-shelf availability, a single short procedure, regenerative cartilage restoration, and long-term durability in a single treatment approach.

A Different Regenerative Model

GelrinC® represents a fundamentally different regenerative approach designed to simplify one of orthopedics’ most complex treatment categories.

The product is an acellular hydrogel composed of polyethylene glycol and denatured fibrinogen, delivered into a cartilage defect in liquid form and then cured into a solid degradable hydrogel implant using ultraviolet light. The implant is designed to gradually resorb in a synchronized manner as native surrounding cells migrate inward, supporting regeneration of hyaline-like cartilage tissue over time.

From a practical standpoint, the workflow is materially simpler than cell-based alternatives. The procedure takes approximately 10 minutes, can be performed using open or minimally invasive techniques, and does not require tissue harvesting, cell culturing, or delayed reimplantation. Surgeons use the product at the point of care rather than coordinating a multi-step treatment pathway.

That combination of procedural simplicity and regenerative intent is central to the company's commercial thesis.

Clinical Progress and Commercial Preparation

Clinical data have provided the early foundation for that thesis.

In a Phase II study involving 56 patients across Northern Europe and Israel, GelrinC® demonstrated statistically significant improvement in its primary endpoint measuring KOOS outcomes at 24 months. GelrinC® treatment resulted in 100% greater overall KOOS (Knee Injury and Osteoarthritis Outcome Score) clinical outcomes compared to microfracture controls, including significant improvements in pain, function, and patient recovery measures, compared to microfracture controls. In parallel, quantitative MOCART imaging scores - a validated, FDA-accepted MRI assessment method - suggested near-complete structural repair and among the highest reported cartilage repair outcomes in the field. No serious adverse events were reported.

Those results supported CE Mark marketing approval in Europe, where Regentis is now actively building a commercialization infrastructure and physician adoption pathways ahead of planned market entry.

In April, the company announced a collaboration with Humanitas Research Hospital in Milan, one of Europe's leading orthopedic and sports medicine centers, alongside internationally recognized cartilage regeneration expert Prof. Elizaveta Kon. The initiative is part of Regentis’ broader strategy to establish a European Centers of Excellence network designed to support surgeon education, clinical guidance, and large-scale physician adoption ahead of commercialization.

Commercial readiness is also showing up operationally. In March, Regentis announced a newly developed solvent-free manufacturing process that more than quadruples GelrinC® production yield per batch. Beyond improving production economics, the manufacturing advancement suggests active preparation for broader commercial deployment.

The U.S. Regulatory Path

In the United States, GelrinC® is advancing through a pivotal FDA study under an Investigational Device Exemption pathway.

The study uses a single-arm design with historical microfracture controls previously accepted by regulators, rather than a concurrent randomized comparator arm. Enrollment is targeted at 80 patients, with more than half already recruited and treated according to company disclosures.

If enrollment proceeds as expected, the program could move toward PMA submission in late 2027.

Orthopedic innovation often moves slowly, particularly in categories where legacy procedures remain entrenched despite well-understood limitations. Knee cartilage repair appears to be one of those markets. Regentis is pursuing an opportunity built around procedural simplicity, regenerative intent, and commercial practicality in a category where those elements have rarely aligned in a single product.

For more information, visit the company’s website at www.regentis.co.il .

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the Company’s newsroom at ibn.fm/RGNT